APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

VMAT2 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global VMAT2 Inhibitor Market Outlook and Growth Opportunities 2026

Report ID 174047170429 December 2025198 pages

Choose your research edition.

Industry ResearchVMAT2 Inhibitor Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal VMAT2 Inhibitor Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal VMAT2 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VMAT2 Inhibitor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal VMAT2 Inhibitor Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global VMAT2 Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for VMAT2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for VMAT2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for VMAT2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the VMAT2 Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the VMAT2 Inhibitor market include Teva, Sandoz, Mylan, Zydus, Sun Pharmaceutical, Neurocrine Biosciences, Lupin, Hetero and Dr. Reddy's Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global VMAT2 Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of VMAT2 Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents VMAT2 Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the VMAT2 Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

VMAT2 Inhibitor Segment by Company

Teva

Sandoz

Mylan

Zydus

Sun Pharmaceutical

Neurocrine Biosciences

Lupin

Hetero

Dr. Reddy's Laboratories

Chartwell Pharmaceuticals

Bionpharma

Bausch Health

Apotex

Actavis Laboratories

VMAT2 Inhibitor Segment by Type

Deutetrabenazine

Tetrabenazine

Valbenazine

VMAT2 Inhibitor Segment by Application

Chorea Caused by Huntington's Disease

Tardive Dyskinesia

Other

VMAT2 Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global VMAT2 Inhibitor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions VMAT2 Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify VMAT2 Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze VMAT2 Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VMAT2 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VMAT2 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VMAT2 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the VMAT2 Inhibitor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global VMAT2 Inhibitor industry.

Chapter 3: Detailed analysis of VMAT2 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of VMAT2 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of VMAT2 Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. VMAT2 Inhibitor Industry Trends Table 2. VMAT2 Inhibitor Industry Drivers Table 3. VMAT2 Inhibitor Industry Opportunities and Challenges Table 4. VMAT2 Inhibitor Industry Restraints Table 5. Global VMAT2 Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global VMAT2 Inhibitor Revenue Share by Company (2021-2026) Table 7. Global VMAT2 Inhibitor Sales Volume by Company (K Units) & (2021-2026) Table 8. Global VMAT2 Inhibitor Sales Volume Share by Company (2021-2026) Table 9. Global VMAT2 Inhibitor Average Price (US$/Unit) of Company (2021-2026) Table 10. Global VMAT2 Inhibitor Company Ranking, (2024-2026) & (USD Million) Table 11. Global VMAT2 Inhibitor Key Company Manufacturing Base & Headquarters Table 12. Global VMAT2 Inhibitor Company, Product Type & Application Table 13. Global VMAT2 Inhibitor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global VMAT2 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Deutetrabenazine Table 18. Significant Companies of Tetrabenazine Table 19. Significant Companies of Valbenazine Table 20. Global VMAT2 Inhibitor Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global VMAT2 Inhibitor Sales Volume by Type (2021-2026) & (K Units) Table 22. Global VMAT2 Inhibitor Sales Volume by Type (2027-2032) & (K Units) Table 23. Global VMAT2 Inhibitor Sales Volume Share by Type (2021-2026) Table 24. Global VMAT2 Inhibitor Sales Volume Share by Type (2027-2032) Table 25. Global VMAT2 Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global VMAT2 Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global VMAT2 Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global VMAT2 Inhibitor Sales Value Share by Type (2021-2026) Table 29. Global VMAT2 Inhibitor Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Chorea Caused by Huntington's Disease Table 31. Significant Companies of Tardive Dyskinesia Table 32. Significant Companies of Other Table 33. Global VMAT2 Inhibitor Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global VMAT2 Inhibitor Sales Volume by Application (2021-2026) & (K Units) Table 35. Global VMAT2 Inhibitor Sales Volume by Application (2027-2032) & (K Units) Table 36. Global VMAT2 Inhibitor Sales Volume Share by Application (2021-2026) Table 37. Global VMAT2 Inhibitor Sales Volume Share by Application (2027-2032) Table 38. Global VMAT2 Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global VMAT2 Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global VMAT2 Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global VMAT2 Inhibitor Sales Value Share by Application (2021-2026) Table 42. Global VMAT2 Inhibitor Sales Value Share by Application (2027-2032) Table 43. Global VMAT2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global VMAT2 Inhibitor Sales by Region (2021-2026) & (K Units) Table 45. Global VMAT2 Inhibitor Sales Market Share by Region (2021-2026) Table 46. Global VMAT2 Inhibitor Sales by Region (2027-2032) & (K Units) Table 47. Global VMAT2 Inhibitor Sales Market Share by Region (2027-2032) Table 48. Global VMAT2 Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global VMAT2 Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global VMAT2 Inhibitor Sales Value Share by Region (2021-2026) Table 51. Global VMAT2 Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global VMAT2 Inhibitor Sales Value Share by Region (2027-2032) Table 53. Global VMAT2 Inhibitor Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global VMAT2 Inhibitor Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global VMAT2 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global VMAT2 Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global VMAT2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 58. Global VMAT2 Inhibitor Sales Market Share by Country (2021-2026) Table 59. Global VMAT2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 60. Global VMAT2 Inhibitor Sales Market Share by Country (2027-2032) Table 61. Global VMAT2 Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global VMAT2 Inhibitor Sales Value Market Share by Country (2021-2026) Table 63. Global VMAT2 Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global VMAT2 Inhibitor Sales Value Market Share by Country (2027-2032) Table 65. Teva Company Information Table 66. Teva Business Overview Table 67. Teva VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Teva VMAT2 Inhibitor Product Portfolio Table 69. Teva Recent Development Table 70. Sandoz Company Information Table 71. Sandoz Business Overview Table 72. Sandoz VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Sandoz VMAT2 Inhibitor Product Portfolio Table 74. Sandoz Recent Development Table 75. Mylan Company Information Table 76. Mylan Business Overview Table 77. Mylan VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Mylan VMAT2 Inhibitor Product Portfolio Table 79. Mylan Recent Development Table 80. Zydus Company Information Table 81. Zydus Business Overview Table 82. Zydus VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Zydus VMAT2 Inhibitor Product Portfolio Table 84. Zydus Recent Development Table 85. Sun Pharmaceutical Company Information Table 86. Sun Pharmaceutical Business Overview Table 87. Sun Pharmaceutical VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Sun Pharmaceutical VMAT2 Inhibitor Product Portfolio Table 89. Sun Pharmaceutical Recent Development Table 90. Neurocrine Biosciences Company Information Table 91. Neurocrine Biosciences Business Overview Table 92. Neurocrine Biosciences VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Neurocrine Biosciences VMAT2 Inhibitor Product Portfolio Table 94. Neurocrine Biosciences Recent Development Table 95. Lupin Company Information Table 96. Lupin Business Overview Table 97. Lupin VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Lupin VMAT2 Inhibitor Product Portfolio Table 99. Lupin Recent Development Table 100. Hetero Company Information Table 101. Hetero Business Overview Table 102. Hetero VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Hetero VMAT2 Inhibitor Product Portfolio Table 104. Hetero Recent Development Table 105. Dr. Reddy's Laboratories Company Information Table 106. Dr. Reddy's Laboratories Business Overview Table 107. Dr. Reddy's Laboratories VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Dr. Reddy's Laboratories VMAT2 Inhibitor Product Portfolio Table 109. Dr. Reddy's Laboratories Recent Development Table 110. Chartwell Pharmaceuticals Company Information Table 111. Chartwell Pharmaceuticals Business Overview Table 112. Chartwell Pharmaceuticals VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Chartwell Pharmaceuticals VMAT2 Inhibitor Product Portfolio Table 114. Chartwell Pharmaceuticals Recent Development Table 115. Bionpharma Company Information Table 116. Bionpharma Business Overview Table 117. Bionpharma VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Bionpharma VMAT2 Inhibitor Product Portfolio Table 119. Bionpharma Recent Development Table 120. Bausch Health Company Information Table 121. Bausch Health Business Overview Table 122. Bausch Health VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Bausch Health VMAT2 Inhibitor Product Portfolio Table 124. Bausch Health Recent Development Table 125. Apotex Company Information Table 126. Apotex Business Overview Table 127. Apotex VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Apotex VMAT2 Inhibitor Product Portfolio Table 129. Apotex Recent Development Table 130. Actavis Laboratories Company Information Table 131. Actavis Laboratories Business Overview Table 132. Actavis Laboratories VMAT2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Actavis Laboratories VMAT2 Inhibitor Product Portfolio Table 134. Actavis Laboratories Recent Development Table 135. Key Raw Materials Table 136. Raw Materials Key Suppliers Table 137. VMAT2 Inhibitor Distributors List Table 138. VMAT2 Inhibitor Customers List Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. VMAT2 Inhibitor Product Image Figure 2. Global VMAT2 Inhibitor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global VMAT2 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 4. Global VMAT2 Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global VMAT2 Inhibitor Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global VMAT2 Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Deutetrabenazine Image Figure 10. Tetrabenazine Image Figure 11. Valbenazine Image Figure 12. Global VMAT2 Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global VMAT2 Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global VMAT2 Inhibitor Sales Volume Share by Type (2021-2032) Figure 15. Global VMAT2 Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global VMAT2 Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global VMAT2 Inhibitor Sales Value Share by Type (2021-2032) Figure 18. Chorea Caused by Huntington's Disease Image Figure 19. Tardive Dyskinesia Image Figure 20. Other Image Figure 21. Global VMAT2 Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global VMAT2 Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global VMAT2 Inhibitor Sales Volume Share by Application (2021-2032) Figure 24. Global VMAT2 Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global VMAT2 Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global VMAT2 Inhibitor Sales Value Share by Application (2021-2032) Figure 27. Global VMAT2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global VMAT2 Inhibitor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global VMAT2 Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global VMAT2 Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America VMAT2 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 32. North America VMAT2 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe VMAT2 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 34. Europe VMAT2 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific VMAT2 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific VMAT2 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America VMAT2 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 38. South America VMAT2 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa VMAT2 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa VMAT2 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt VMAT2 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. VMAT2 Inhibitor Value Chain Figure 126. Manufacturing Cost Structure Figure 127. VMAT2 Inhibitor Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Deutetrabenazine
  • Tetrabenazine
  • Valbenazine
Applications
  • Chorea Caused by Huntington's Disease
  • Tardive Dyskinesia
  • Other
Companies covered
  • Teva
  • Sandoz
  • Mylan
  • Zydus
  • Sun Pharmaceutical
  • Neurocrine Biosciences
  • Lupin
  • Hetero
  • Dr. Reddy's Laboratories
  • Chartwell Pharmaceuticals
  • Bionpharma
  • Bausch Health
  • Apotex
  • Actavis Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global VMAT2 Inhibitor Sales Value (2021-2032)
  4. 1.2.2 Global VMAT2 Inhibitor Sales Volume (2021-2032)
  5. 1.2.3 Global VMAT2 Inhibitor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 VMAT2 Inhibitor Market Dynamics
  1. 2.1 VMAT2 Inhibitor Industry Trends
  2. 2.2 VMAT2 Inhibitor Industry Drivers
  3. 2.3 VMAT2 Inhibitor Industry Opportunities and Challenges
  4. 2.4 VMAT2 Inhibitor Industry Restraints
3 VMAT2 Inhibitor Market by Company
  1. 3.1 Global VMAT2 Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global VMAT2 Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global VMAT2 Inhibitor Sales Volume by Company (2021-2026)
  4. 3.4 Global VMAT2 Inhibitor Average Price by Company (2021-2026)
  5. 3.5 Global VMAT2 Inhibitor Company Ranking (2024-2026)
  6. 3.6 Global VMAT2 Inhibitor Company Manufacturing Base and Headquarters
  7. 3.7 Global VMAT2 Inhibitor Company Product Type and Application
  8. 3.8 Global VMAT2 Inhibitor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global VMAT2 Inhibitor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 VMAT2 Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 VMAT2 Inhibitor Market by Type
  1. 4.1 VMAT2 Inhibitor Type Introduction
  2. 4.1.1 Deutetrabenazine
  3. 4.1.2 Tetrabenazine
  4. 4.1.3 Valbenazine
  5. 4.2 Global VMAT2 Inhibitor Sales Volume by Type
  6. 4.2.1 Global VMAT2 Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global VMAT2 Inhibitor Sales Volume by Type (2021-2032)
  8. 4.2.3 Global VMAT2 Inhibitor Sales Volume Share by Type (2021-2032)
  9. 4.3 Global VMAT2 Inhibitor Sales Value by Type
  10. 4.3.1 Global VMAT2 Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global VMAT2 Inhibitor Sales Value by Type (2021-2032)
  12. 4.3.3 Global VMAT2 Inhibitor Sales Value Share by Type (2021-2032)
5 VMAT2 Inhibitor Market by Application
  1. 5.1 VMAT2 Inhibitor Application Introduction
  2. 5.1.1 Chorea Caused by Huntington's Disease
  3. 5.1.2 Tardive Dyskinesia
  4. 5.1.3 Other
  5. 5.2 Global VMAT2 Inhibitor Sales Volume by Application
  6. 5.2.1 Global VMAT2 Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global VMAT2 Inhibitor Sales Volume by Application (2021-2032)
  8. 5.2.3 Global VMAT2 Inhibitor Sales Volume Share by Application (2021-2032)
  9. 5.3 Global VMAT2 Inhibitor Sales Value by Application
  10. 5.3.1 Global VMAT2 Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global VMAT2 Inhibitor Sales Value by Application (2021-2032)
  12. 5.3.3 Global VMAT2 Inhibitor Sales Value Share by Application (2021-2032)
6 VMAT2 Inhibitor Regional Sales and Value Analysis
  1. 6.1 Global VMAT2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global VMAT2 Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global VMAT2 Inhibitor Sales by Region: 2021-2026
  4. 6.2.2 Global VMAT2 Inhibitor Sales by Region (2027-2032)
  5. 6.3 Global VMAT2 Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global VMAT2 Inhibitor Sales Value by Region (2021-2032)
  7. 6.4.1 Global VMAT2 Inhibitor Sales Value by Region: 2021-2026
  8. 6.4.2 Global VMAT2 Inhibitor Sales Value by Region (2027-2032)
  9. 6.5 Global VMAT2 Inhibitor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America VMAT2 Inhibitor Sales Value (2021-2032)
  12. 6.6.2 North America VMAT2 Inhibitor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe VMAT2 Inhibitor Sales Value (2021-2032)
  15. 6.7.2 Europe VMAT2 Inhibitor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific VMAT2 Inhibitor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific VMAT2 Inhibitor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America VMAT2 Inhibitor Sales Value (2021-2032)
  21. 6.9.2 South America VMAT2 Inhibitor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa VMAT2 Inhibitor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa VMAT2 Inhibitor Sales Value Share by Country, 2025 VS 2032
7 VMAT2 Inhibitor Country-level Sales and Value Analysis
  1. 7.1 Global VMAT2 Inhibitor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global VMAT2 Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global VMAT2 Inhibitor Sales by Country (2021-2032)
  4. 7.3.1 Global VMAT2 Inhibitor Sales by Country (2021-2026)
  5. 7.3.2 Global VMAT2 Inhibitor Sales by Country (2027-2032)
  6. 7.4 Global VMAT2 Inhibitor Sales Value by Country (2021-2032)
  7. 7.4.1 Global VMAT2 Inhibitor Sales Value by Country (2021-2026)
  8. 7.4.2 Global VMAT2 Inhibitor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt VMAT2 Inhibitor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt VMAT2 Inhibitor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt VMAT2 Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva VMAT2 Inhibitor Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sandoz
  8. 8.2.1 Sandoz Company Information
  9. 8.2.2 Sandoz Business Overview
  10. 8.2.3 Sandoz VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sandoz VMAT2 Inhibitor Product Portfolio
  12. 8.2.5 Sandoz Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mylan VMAT2 Inhibitor Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 Zydus
  20. 8.4.1 Zydus Company Information
  21. 8.4.2 Zydus Business Overview
  22. 8.4.3 Zydus VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Zydus VMAT2 Inhibitor Product Portfolio
  24. 8.4.5 Zydus Recent Developments
  25. 8.5 Sun Pharmaceutical
  26. 8.5.1 Sun Pharmaceutical Company Information
  27. 8.5.2 Sun Pharmaceutical Business Overview
  28. 8.5.3 Sun Pharmaceutical VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sun Pharmaceutical VMAT2 Inhibitor Product Portfolio
  30. 8.5.5 Sun Pharmaceutical Recent Developments
  31. 8.6 Neurocrine Biosciences
  32. 8.6.1 Neurocrine Biosciences Company Information
  33. 8.6.2 Neurocrine Biosciences Business Overview
  34. 8.6.3 Neurocrine Biosciences VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Neurocrine Biosciences VMAT2 Inhibitor Product Portfolio
  36. 8.6.5 Neurocrine Biosciences Recent Developments
  37. 8.7 Lupin
  38. 8.7.1 Lupin Company Information
  39. 8.7.2 Lupin Business Overview
  40. 8.7.3 Lupin VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lupin VMAT2 Inhibitor Product Portfolio
  42. 8.7.5 Lupin Recent Developments
  43. 8.8 Hetero
  44. 8.8.1 Hetero Company Information
  45. 8.8.2 Hetero Business Overview
  46. 8.8.3 Hetero VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hetero VMAT2 Inhibitor Product Portfolio
  48. 8.8.5 Hetero Recent Developments
  49. 8.9 Dr. Reddy's Laboratories
  50. 8.9.1 Dr. Reddy's Laboratories Company Information
  51. 8.9.2 Dr. Reddy's Laboratories Business Overview
  52. 8.9.3 Dr. Reddy's Laboratories VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Dr. Reddy's Laboratories VMAT2 Inhibitor Product Portfolio
  54. 8.9.5 Dr. Reddy's Laboratories Recent Developments
  55. 8.10 Chartwell Pharmaceuticals
  56. 8.10.1 Chartwell Pharmaceuticals Company Information
  57. 8.10.2 Chartwell Pharmaceuticals Business Overview
  58. 8.10.3 Chartwell Pharmaceuticals VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Chartwell Pharmaceuticals VMAT2 Inhibitor Product Portfolio
  60. 8.10.5 Chartwell Pharmaceuticals Recent Developments
  61. 8.11 Bionpharma
  62. 8.11.1 Bionpharma Company Information
  63. 8.11.2 Bionpharma Business Overview
  64. 8.11.3 Bionpharma VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bionpharma VMAT2 Inhibitor Product Portfolio
  66. 8.11.5 Bionpharma Recent Developments
  67. 8.12 Bausch Health
  68. 8.12.1 Bausch Health Company Information
  69. 8.12.2 Bausch Health Business Overview
  70. 8.12.3 Bausch Health VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bausch Health VMAT2 Inhibitor Product Portfolio
  72. 8.12.5 Bausch Health Recent Developments
  73. 8.13 Apotex
  74. 8.13.1 Apotex Company Information
  75. 8.13.2 Apotex Business Overview
  76. 8.13.3 Apotex VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Apotex VMAT2 Inhibitor Product Portfolio
  78. 8.13.5 Apotex Recent Developments
  79. 8.14 Actavis Laboratories
  80. 8.14.1 Actavis Laboratories Company Information
  81. 8.14.2 Actavis Laboratories Business Overview
  82. 8.14.3 Actavis Laboratories VMAT2 Inhibitor Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Actavis Laboratories VMAT2 Inhibitor Product Portfolio
  84. 8.14.5 Actavis Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 VMAT2 Inhibitor Value Chain Analysis
  2. 9.1.1 VMAT2 Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 VMAT2 Inhibitor Sales Mode & Process
  6. 9.2 VMAT2 Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 VMAT2 Inhibitor Distributors
  9. 9.2.3 VMAT2 Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst